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Abstract
Objective—The objectives of this cross-sectional study were to determine correlates of syphilis
seroprevalence among HIV-infected and -uninfected antenatal attendees in an African multisite
clinical trial, and to improve strategies for maternal syphilis prevention.
Results—A total of 2270 (86%) women were HIV-infected and 366 (14%) were HIV-uninfected.
One hundred seventy-five (6.6%) were syphilis-seropositive (7.3% among HIV-infected and 2.6%
HIV-uninfected women). Statistically significant correlates included geographic site (odds ratio [OR]
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= 4.5, Blantyre; OR = 3.2, Lilongwe; OR = 9.0, Lusaka vs. Dar es Salaam referent); HIV infection
(OR = 3.3); age 20 to 24 years (OR = 2.5); being divorced, widowed, or separated (OR = 2.9); genital
ulcer treatment in the last year (OR = 2.9); history of stillbirth (OR = 2.8, one stillbirth; OR = 4.3,
2–5 stillbirths); and history of preterm delivery (OR = 2.7, one preterm delivery).
Conclusion—Many women without identified risk factors were syphilis-seropositive. Younger
HIV-infected women were at highest risk. Universal integrated antenatal HIV and syphilis screening
and treatment is essential in sub-Saharan African settings.
Syphilis is a serious cause of maternal and infant morbidity and mortality.1–5 Syphilis during
pregnancy is associated with stillbirth, spontaneous abortion, preterm birth, and intrauterine
growth restriction.6 A Treponema pallidum-infected newborn may exhibit
hepatosplenomegaly, failure to thrive, and high neonatal mortality. 5,7–9 In addition to these
serious reproductive outcomes, syphilis is a well-documented cofactor for horizontal (sexual),
10–12 as well as vertical (mother to child), transmission of HIV.10,13,14 In sub-Saharan Africa
and elsewhere, syphilis and HIV serve as synergistic infections, each exacerbating the
transmission of the other.15,16
Women in resource-limited settings may not receive routine screening for syphilis in antenatal
care, and even if they are screened, treatment for infected mothers may be unavailable.7 In a
chart review of 622 women receiving public sector antenatal care in Lusaka, Zambia, the rapid
plasma reagin (RPR) assay was recorded in 81% of records, whereas only 2 of 44 positive
results had treatment documented in their records at a time of penicillin supply shortages
(1999–2000) (R. MacDonald and SHV, unpublished data; M. Sinkala, personal
communication, May 2005).
Reported syphilis rates vary markedly between and within sub-Saharan African populations.
Antenatal syphilis prevalence rates in Malawi, Tanzania, and Zambia are reported as 2.7%
(year 2003; Venereal Diseases Reference Laboratory tests [VDRL], no confirmatory testing),
17 7.2% (year 2000; RPR confirmed with T. pallidum hemagglutination assay [TPHA]),18 and
8.2% (2001; RPR confirmed with TPHA),19 respectively. Regional seroprevalence differences
may reflect a variety of sociocultural and economic factors, varying surveillance methods, and
differential access to syphilis diagnosis and treatment.20 We examined demographic, sexual
risk, and obstetric characteristics to predict syphilis sero-prevalence among HIV-infected and
-uninfected antenatal attendees enrolled in a multisite clinical trial in Africa.
Methods
Study Setting and Population
The HIVNET 024 trial was a randomized, double-blind, placebo-controlled phase 3 clinical
trial of antibiotics to prevent perinatal HIV transmission and preterm birth by reducing
chorioamnionitis.21,22 The intervention studied in the trial was a relatively inexpensive (<$5
US), 2-course antibiotic prophylactic regimen. Trial participants were recruited in 4 sub-
Saharan African cities: Blantyre and Lilongwe, Malawi; Lusaka, Zambia; and Dar es Salaam,
Tanzania. Enrollment started in July 2001 and was completed in February 2003. Consenting
pregnant women were screened for HIV infection between 16 and 23 weeks gestation during
an antenatal clinic visit before enrollment into the trial. Laboratory evaluations included HIV-1
serology screening by dual rapid test algorithm and Western blot confirmation of all positive
or indeterminate results at 3 sites, whereas the Dar es Salaam site performed 2 enzyme-linked
immunosorbent assays (ELISAs): Dade Behring Enzygnost anti-HIV-1/2 Plus(first ELISA)
followed by Abbott Murex Wellcozyme anti-HIV-1 recombinant with discrepant results
between the two ELISAs being confirmed by Western blot. Additional study laboratory
evaluations included comprehensive screening for sexually transmitted infections (STIs) and
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complete blood counts.21 At 20 to 24 weeks gestational age, women were randomized to
receive either 250 mg metronidazole 3 times a day and 250 mg erythromycin orally 3 times
daily for 7 days or placebo for the control group. Participants were also given 250 mg
metronidazole and 500 mg ampicillin (or placebo) at the 26- to 30-week visit to be taken at the
onset of labor continuing after delivery 3 times daily until the 1-week course was completed.
Five HIV-infected women were recruited for every one HIV-uninfected woman at the 2 Malawi
and Zambian sites, whereas the Dar es Salaam site recruited only HIV-infected women as per
the design of the parent trial. The primary study outcome was mother-to-child transmission of
HIV, whereas secondary outcomes included other causes of morbidity and mortality such as
preterm birth. Sociodemographic, living environment, obstetric, and sexual history data were
collected at the study enrollment visit using a standardized structured questionnaire enabling
the present nested study. Research nurses interviewed enrolled participants confidentially in
private rooms. The study was approved by U.S. and in-country institutional ethical review
boards or committees in each country. Written informed consent was obtained from all enrolled
participants.
Laboratory Procedures
HIV testing was performed at a screening visit according to site-specific procedures using
either conventional HIV ELISA tests or dual HIV rapid tests. These tests were validated by a
central reference laboratory in the United States. HIV-infected women were offered mother-
to-child transmission prophylaxis with nevirapine.23,24 Women were tested for syphilis using
RPR tests (Blantyre, Lilongwe, and Lusaka) or VDRL tests (Dar es Salaam) as part of preentry
evaluations at the enrollment visit. Confirmation of the syphilis screening test was performed
with the microhemagglutination T. pallidum test (MHA-TP) (Lilongwe), T. pallidum particle
agglutination test (TPPA) (Dar es Salaam), or TPHA (Blantyre). Both TPPA and TPHA tests
were used to confirm positive RPR samples from Lusaka. Women with a reactive syphilis test
were treated with intramuscular benzathine penicillin at no cost.
Statistical Analysis
For purposes of this study, a confirmed test was used as the basis for syphilis diagnosis. Data
obtained at the enrollment visit (20–24 weeks gestation) were used for this study. A woman
was considered to have maternal syphilis if, at the time of HIVNET 024 enrollment, her serum
was reactive according to one of the screening and one of the confirmatory tests. Higher
socioeconomic status was estimated from data on availability of electricity or running water
in the home.
Associations between syphilis serostatus and demographic, sexual history, or obstetric
variables were assessed using odds ratios (ORs) and chi-square, Student t, or Fisher exact tests,
as appropriate, to determine statistical significance. Multivariable logistic regression analysis
was used to further investigate those associations that were significant at a P <0.05 (2-tailed)
level with syphilis sero-prevalence in the bivariate analyses. Findings are presented as adjusted
odds ratios (ORadj) with corresponding 95% confidence intervals (95% CIs) and/or P values.
The logistic models were performed for the overall population of HIV-infected and -uninfected
women and separately stratified by HIV infection status. All statistical analyses were
performed with SAS version 9.1 (SAS, Inc., Cary, NC).
Results
Study Population, Syphilis Seroprevalence
Of 2661 women who gave informed consent for enrollment into HIVNET 024, 2636 (99%)
had a syphilis screening test and, if the screening test was positive, a confirmatory test. All
2636 of these women were included in this syphilis substudy. As per the study design, 2270
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(86%) were HIV-infected and 366 (14%) were HIV-uninfected. At enrollment, 175 (6.6%)
women were confirmed syphilis positive, 7.3% among HIV-infected and 2.5% among HIV-
uninfected (OR = 3.1, 95% CI = 1.6–6.2). Overall site-specific seroprevalence rates ranged
from 1.4% in Dar es Salaam, Tanzania, to 11.7% in Lusaka, Zambia. The rates were
intermediate in Lilongwe (5.1%) and Blantrye (6.3%), Malawi (Table 1). Among the HIV-
infected women, the site-specific syphilis seroprevalences were: 1.4% in Dar es Salaam, 5.9%
in Lilongwe, 7.3% in Blantrye, and 13.0% in Lusaka. Among the HIV-uninfected women, the
site-specific confirmed syphilis rates were: 1.1% in Blantyre, 1.4% in Lilongwe, and 4.9% in
Lusaka.
Sociodemographic Characteristics, Sexual and Obstetric History
In bivariate analyses, women were more likely to be syphilis-seropositive if they came from
the Malawi or Zambia sites, were HIV-infected, were 20 to 24 years old, had completed less
than 6 years of formal education, were illiterate, were divorced/separated/widowed, were of
lower socioeconomic status, had a greater number of lifetime sexual partners, had been treated
for genital ulcers in the last year, had a greater number of past pregnancies, had a history of
stillbirth, and a history of preterm delivery (Table 1).
In bivariate analyses, the following variables were not significant: years of formal education
of spouse/partner, occupation, spouse/partner’s occupation, housing type, use of gas/electrical
or charcoal stove or firewood for cooking, number of lifetime sexual partners in the current
pregnancy, condom use during the current pregnancy, having been treated for abnormal vaginal
discharge in the last year, and number of abortions or miscarriages.
Women at each of the 4 sites were of similar age, education, literacy, marital status, and
occupation, except that women in Dar es Salaam were of higher socioeconomic status as
measured by electricity and running water on their premises and use of a paraffin stove or
firewood for cooking. Results of site-specific analyses were very similar to the findings of the
overall analysis (data not shown).
Correlates of Syphilis Seroprevalence
In the multivariable logistic regression analysis for the 4 sites combined, 7 factors were found
to be independent and statistically significant correlates of syphilis seroprevalence among the
antenatal attendees (Table 2): geographic site (OR = 4.5, Blantyre; OR = 3.2, Lilongwe; OR
= 9.0, Lusaka, vs. Dar es Salaam referent population), HIV infection (OR = 3.3), maternal age
20 to 24 years (OR = 2.5 vs. age 16–19 years), being divorced/widowed/ separated (OR = 2.9
vs. married or living with partner), having had treatment for genital ulcers in the last year (OR
= 2.9), history of stillbirth (OR = 2.8 for one stillbirth; OR = 4.3 for 2–5 stillbirths), or having
had a preterm delivery (OR = 2.7 for one preterm delivery).
The same variables were found significant in bivariate analyses for the HIV-infected women
as for the combined cohort and were used in a multivariable analysis assessment. The
multivariable logistic regression analysis results were similar for the combined HIV-infected
and -uninfected cohort (n = 2636) as for the HIV-infected cohort alone (n = 2270) (results not
shown for HIV-infected cohort). There were 9 syphilis-seropositive women among the HIV-
uninfected cohort of women (n = 366). No variables were found to be independent and
statistically significant correlates of syphilis seroreactivity among the HIV-uninfected women
in multivariable analysis.
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There were variations in syphilis seroprevalence among sites, with the Lusaka, Zambia, site
having an especially high seroprevalence (11.7%). Women with HIV infection were more
likely to be syphilis-seropositive as were women who were divorced, separated, or widowed.
Women with a history of stillbirth or preterm delivery were significantly more likely to be
syphilis-seropositive, confirming the well-known reproductive health consequences of
maternal and congenital syphilis. A surprising result was the significant association of syphilis
among women in the 20- to 24-year age group as compared with older women. Typically,
syphilis rates are highest in older women, but given 86% of women enrolled in the study were
HIV-infected and the extremely limited access to antiretroviral therapy in the time period of
the study, older women with syphilis and HIV may well have died before study
commencement, distorting the age-risk associations.25 Although the number of sexual partners
during the current pregnancy was not significantly associated with syphilis, the number of
lifetime sexual partners was found to be statistically significant on bivariate and multivariable
analyses, suggesting that syphilis risk is not specific to the time of pregnancy per se.10,26
Higher syphilis risk is documented in divorced and widowed women in Senegal,27 although
single marital status was the risk factor noted in a previous Tanzania study.28 Previous studies
related to pregnant women in developing countries reported the following risk factors for
maternal syphilis, similar to our findings: HIV infection,29 history of stillbirth,30 history of
preterm delivery, 31 previous perinatal death,32 high-risk sexual behaviors,33 history of
abortion,34 genital ulcer disease,35 and lower socioeconomic status.36 The economic indicators
in this study (presence of water or electricity in the home) suggest that antenatal attendees in
Dar es Salaam had a higher socioeconomic status, perhaps associated with lower sexual and
syphilis risks. Higher socioeconomic status is associated with decreased syphilis seroreactivity.
33,37,38 A history of stillbirth was significantly associated with syphilis seroreactivity in our
study; in southern Africa, up to half of all stillbirths are found in syphilis-seroreactive women,
with ≤25% of all stillbirths being attributed to syphilis.39
In a study of 1058 HIV-infected women in Dar es Salaam, Tanzania (2001), antenatal attendees,
independent risk factors for syphilis seroreactivity (positive on both VDRL and TPHA) were:
age 20 to 24 years and 30 to 34 years (compared with women 15–19 years old), abnormal
vaginal discharge in the past year, a genital ulcer on examination, or current Trichomonas
vaginalis infection.40 Women who were fully supported by their male partners were at a
reduced risk of active syphilis compared with those with their own personal income source.40
Inefficient and ineffective antenatal syphilis screening programs in developing countries are
well documented.7,41–44 Although each of the women enrolled in this study was screened for
syphilis and, if reactive, treated, we do not know the coverage rates of the antenatal syphilis
screening programs in these 4 sites for nonresearch patients. In Zambia and Malawi, in
particular, high seroprevalence rates suggest the need to improve syphilis screening and
treatment in concert with other essential antenatal services.45 Advocacy by developing country
governments and international economic and/or technical assistance is needed to support
strapped health workers and systems to achieve a long-term goal of sustainability.
Our seroprevalence findings are a legitimate comparison between 4 African cities, but they
might not reflect background syphilis seroprevalence because: 1) 86% of the women were
HIV-infected as a result of the design of the parent clinical trial; 2) antenatal attendees who
consented to join the research study may have been more likely to have had STIs or history of
obstetric complication than other women; and 3) recruitment for the study occurred among
women already in the antenatal care system; thus, women who joined the study were those
who “booked early” because enrollment only occurred from 20 to 24 weeks gestation. These
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selection factors indicate that our study seroprevalence is not generalizable; higher syphilis
seroprevalence might be expected from HIV-infected women; lower rates might be seen in
women booking relatively early (20–24 weeks gestation) for antenatal care; higher rates might
be seen in women booking early as a result of reproductive tract symptoms; and lower rates
might be seen in women seeking care through research-related programs because they
potentially perceived it of higher quality than the government care system. We did not find the
higher syphilis rates among HIV-infected women in the lower HIV prevalence nation; the
lowest syphilis rates were noted in Tanzania where HIV prevalence is lower than in Malawi
or Zambia.46,47
Antenatal syphilis screening programs must be evaluated for effectiveness and reformed
accordingly. Infants receiving antiretroviral prophylaxis as part of a prevention of mother-to-
child HIV transmission (PMTCT) program have been documented to die of congenital syphilis
in a program in which syphilis screening had not been a part of HIV prevention activities.48
Vertical integration of syphilis screening in antenatal HIV prevention programs is a way to
strengthen existing health systems and to improve on health outcomes, particularly in resource-
limited settings where obstacles to universal antenatal screening may abound48 analogous to
joint HIV and tuberculosis screening that is advocated in high-prevalence regions.49 A routine,
universal, “opt-out” approach to joint syphilis and HIV screening would improve coverage and
care for both.50 In Lilongwe, Malawi, for example, where a mature PMTCT program has
resulted in almost universal acceptance of voluntary counseling and testing (VCT) based on
fingerstick, whole-blood HIV rapid testing, a pilot program is being conducted to routinely
perform syphilis rapid tests (and treatment) during the VCT session.51 Given the high rates of
HIV and syphilis coinfection, antenatal care providers may consider an antenatal attendee’s
marital status and age; if resources are scarce and must be prioritized, those attendees who are
younger, divorced, widowed, or separated are likely to be at higher risk for both infectious
diseases. Although recognition of syphilis risk factors is useful, many women without the risk
factor characteristics were syphilis-seroreactive; universal testing is clearly the superior
approach.
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TABLE 1
Confirmed Syphilis-Seropositive and Baseline Sociodemographic and Sexual/Obstetric History Characteristics Among







Site n = 2,636
  Blantyre, Malawi 559 (21.2) 6.3
  Lilongwe, Malawi 896 (34.0) 5.1
  Dar es Salaam, Tanzania 428 (16.2) 1.4
  Lusaka, Zambia 753 (28.6) 11.7
P <0.0001
HIV serostatus n = 2,636
  Positive 2,270 (86.1) 7.3
  Negative 366 (13.9) 2.5
P = 0.0005
Age in years n = 2,636
  16–19 322 (12.2) 3.7
  20–24 1,013 (38.4) 9.1
  25–29 845 (32.1) 5.3
  30–45 456 (17.3) 5.7
P = 0.0007
Years of formal education
    (completed years)
n = 2,635
  None 233 (8.8) 10.3
  1–5 614 (23.3) 8.5
  6–18 1,788 (67.9) 5.5
P = 0.002
Literate (self-reported) n = 2,636
  Yes 2,051 (77.8) 5.3
  No 585 (22.2) 11.3
P ≤0.0001
Marital status n = 2,636
  Married and/or living with
   partner (referent)
2,431 (92.2) 6.3
  Never married or living
   with partner
141 (5.4) 4.3
  Divorced, separated, or
   widowed
64 (2.4) 23.4
P ≤0.0001
Electricity on premises n = 2,636
  Yes 1,048 (39.8) 5.1
  No 1,588 (60.2) 7.7
P = 0.008
Running water on
   premises
n = 2,636
  Yes 1,084 (41.1) 5.3




















  No 1,552 (58.9) 7.6
P = 0.02
Cook with paraffin stove n = 2,636
  Yes 470 (17.8) 2.3
  No 2,166 (82.2) 7.6
P ≤0.0001
Number of lifetime sexual
   partners including
   spouse or partner
n = 2,617
  1 628 (24.0) 4.6
  2 848 (32.4) 5.7
  3–25 1,141 (43.6) 8.5
P < 0.003
In the last year, treated for
   genital ulcers
n = 2,633
  Yes 93 (3.5) 21.5
  No 2,540 (96.5) 6.1
P ≤ 0.0001
Number of pregnancies,
   including current
n = 2,636
  1 501 (19.0) 4
  2–4 1,712 (65.0) 7.3
  5–12 423 (16.1) 7.1
P = 0.03
Number of stillbirths n = 2,636
  0 2,425 (92) 5.7
  1 180 (6.8) 15.6
  2–5 31 (1.2) 25.8
P ≤0.0001
Number of children born
   >3 wk early
n = 2,636
  0 2,509 (95.2) 6.2
  1 95 (3.6) 16.8
  2–8 32 (1.2) 9.4
P = 0.002
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TABLE 2








   Dar es Salaam, Tanzania (referent) 1.0 1.0
   Blantyre, Malawi 4.7 4.5 (1.4–14.4) 0.01
   Lilongwe, Malawi 3.8 3.2 (1.0–10.0) 0.04
   Lusaka, Zambia 9.3 9.0 (2.9–28.2) 0.0002
HIV infection status
   Seronegative (referent) 1.0 1.0
   Seropositive 3.1 3.3 (1.6–6.9) 0.002
Age (years)
   16–19 (referent) 1.0 1.0
   20–24 2.6 2.5 (1.3–5.0) 0.01
   25–29 1.5 1.2 (0.6–2.6) 0.6
   30–45 1.6 1.4 (0.6–3.2) 0.4
Formal education (completed years)
   0 (referent) 1.0 1.0
   1–5 0.8 0.9 (0.5–1.5) 0.6
   6–18 0.5 0.7 (0.4–1.5) 0.4
Literacy (self-reported)
   Not able to read (referent) 1.0 1.0
   Able to read 0.4 0.7 (0.4–1.2) 0.2
Marital status
   Married/living with partner (referent) 1.0 1.0
   Never married/not living with partner 0.7 0.8 (0.3–2.0) 0.7
   Divorced/separated/widowed 4.5 2.9 (1.5–5.7) 0.001
Presence of utilities on premises
   No electricity (referent) 1.0 1.0
   Electricity on premises 0.6 0.9 (0.6–1.3) 0.5
   No running water on premises (referent) 1.0 1.0
   Running water on premises 0.7 0.9 (0.6–1.3) 0.6
Method used for daily cooking
   No paraffin stove (referent) 1.0 1.0
   Paraffin stove 0.3 1.1 (0.5–2.6) 0.8
Number of lifetime sexual partners including spouse
   1 (referent) 1.0 1.0
   2 1.2 1.1 (0.7–1.9) 0.6
   3–25 1.9 1.5 (1.0–2.4) 0.1
In the last year



















   Not treated for genital ulcers (referent) 1.0 1.0
   Treated for genital ulcers 4.2 2.9 (1.6–5.3) 0.0003
Number of pregnancies, including this pregnancy
   1 (referent) 1.0 1.0
   2–4 1.9 1.5 (0.8–2.5) 0.2
   5–12 1.8 1.2 (0.6–2.7) 0.6
Number of stillbirths
   0 (referent) 1.0 1.0
   1 3.0 2.8 (1.7–4.5) <0.0001
   2–5 5.7 4.3 (1.7–11.2) 0.002
Number of children born >3 wk early
   0 (referent) 1.0 1.0
   1 3.1 2.7 (1.5–5.0) 0.002
   2–8 1.6 1.5 (0.4–5.4) 0.5
RPR indicates rapid plasma reagin assay; VDRL = venereal diseases reference laboratory tests; TPHA = treponema pallidum hemagglutination assay;
MHA-TP = microhemagglutination T. pallidum test; TPPA = T. pallidum particle agglutination test.
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